Effects of intraventricular injections of 6-hydroxydopamine on amine metabolites in rat brain and urine.
The effects in rats of intraventricular injections of 6-hydroxydopamine (6-OHDA) on the urinary excretion 1-3 weeks later of 3-methoxy-4-hydroxyphenethylene glycol (MHPG), 3,4-dihydroxyphenethanol (DHPE), 3-methoxy-4-hydroxyphenethanol (MHPE), p-hydroxyphenylglycol (pHPG), homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were examined. The excretion of MHPG was decreased to 63 and 71% of control on days 7 and 14, respectively, but had returned to control levels by day 23, even though the brain levels were decreased by 87%. Free and total HVA excretion was reduced on both days 7 and 23, but free and total DOPAC was reduced only on day 7. Based on these data, it can be estimated that about 39% of the free and 46% of the total HVA in urine originates in the CNS. The excretion of conjugated HVA was decreased by 70-80%, but this decrease does not support the notion that the conjugated form of HVA is derived principally from the brain and thus serves as a better marker of brain dopamine metabolism, since the level of this metabolite in the brain was not correspondingly decreased but was instead increased. Urinary DOPAC levels were generally more variable and derived to a greater extent from the periphery; therefore, DOPAC appears to be less suitable than HVA as a marker of brain dopamine. The results also indicate that as much as 35% of the urinary MHPG may originate in the CNS, although compensatory changes in catecholamine metabolism in either the brain or in the periphery may have somewhat influenced this estimate. The results also suggest that at least as much pHPG as MHPG in urine derives from the CNS. The data are consistent with the idea that the neutral dopamine metabolites largely derive from the brain, but the relatively small depletion in their brain levels produced by 6-OHDA prevented the exact proportion being determined accurately.
Edwards
D J
DJ
Ravitch
J
J
Knopf
S
S
Sedlock
M L
ML
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D015098:3-Methoxy-4-hydroxyphenylethanol / Q000378:metabolism; D000311:Adrenal Glands / Q000187:drug effects; D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism* / Q000652:urine; D001923:Brain Chemistry / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism; D005026:Ethylene Glycols / Q000378:metabolism; D008401:Gas Chromatography-Mass Spectrometry; D006321:Heart / Q000187:drug effects; D006719:Homovanillic Acid / Q000378:metabolism; D006892:Hydroxydopamines / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D016627:Oxidopamine; D010636:Phenols; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000187:drug effects
D001679:Biogenic Amines; D005026:Ethylene Glycols; D006892:Hydroxydopamines; D010636:Phenols; D015102:3,4-Dihydroxyphenylacetic Acid; C005975:3,4-dihydroxyphenylethanol; C034604:4-hydroxyphenethylene glycol; D015098:3-Methoxy-4-hydroxyphenylethanol; D008734:Methoxyhydroxyphenylglycol; D016627:Oxidopamine; D010626:Phenylethyl Alcohol; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid